Can-Fite BioPharma (CANF) Competitors $1.54 +0.02 (+1.32%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$1.55 +0.01 (+0.65%) As of 03/27/2025 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CANF vs. NAII, CDIO, FNCH, ALLK, UBX, ENLV, BIVI, PMN, LIAN, and NNVCShould you be buying Can-Fite BioPharma stock or one of its competitors? The main competitors of Can-Fite BioPharma include Natural Alternatives International (NAII), Cardio Diagnostics (CDIO), Finch Therapeutics Group (FNCH), Allakos (ALLK), Unity Biotechnology (UBX), Enlivex Therapeutics (ENLV), BioVie (BIVI), ProMIS Neurosciences (PMN), LianBio (LIAN), and NanoViricides (NNVC). These companies are all part of the "pharmaceutical products" industry. Can-Fite BioPharma vs. Natural Alternatives International Cardio Diagnostics Finch Therapeutics Group Allakos Unity Biotechnology Enlivex Therapeutics BioVie ProMIS Neurosciences LianBio NanoViricides Natural Alternatives International (NASDAQ:NAII) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and community ranking. Which has higher valuation and earnings, NAII or CANF? Natural Alternatives International has higher revenue and earnings than Can-Fite BioPharma. Natural Alternatives International is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNatural Alternatives International$121.85M0.18-$7.22M-$1.29-2.67Can-Fite BioPharma$667K8.17-$7.63M-$1.79-0.86 Does the media favor NAII or CANF? In the previous week, Can-Fite BioPharma had 2 more articles in the media than Natural Alternatives International. MarketBeat recorded 6 mentions for Can-Fite BioPharma and 4 mentions for Natural Alternatives International. Natural Alternatives International's average media sentiment score of 0.40 beat Can-Fite BioPharma's score of 0.06 indicating that Natural Alternatives International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natural Alternatives International 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Can-Fite BioPharma 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, NAII or CANF? Natural Alternatives International has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Does the MarketBeat Community believe in NAII or CANF? Natural Alternatives International received 262 more outperform votes than Can-Fite BioPharma when rated by MarketBeat users. Likewise, 76.55% of users gave Natural Alternatives International an outperform vote while only 11.69% of users gave Can-Fite BioPharma an outperform vote. CompanyUnderperformOutperformNatural Alternatives InternationalOutperform Votes27176.55% Underperform Votes8323.45% Can-Fite BioPharmaOutperform Votes911.69%Underperform Votes6888.31% Do analysts recommend NAII or CANF? Can-Fite BioPharma has a consensus price target of $14.00, indicating a potential upside of 809.09%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Can-Fite BioPharma is more favorable than Natural Alternatives International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Natural Alternatives International 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Can-Fite BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Do insiders & institutionals believe in NAII or CANF? 32.4% of Natural Alternatives International shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 20.9% of Natural Alternatives International shares are owned by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is NAII or CANF more profitable? Can-Fite BioPharma has a net margin of 0.00% compared to Natural Alternatives International's net margin of -6.26%. Can-Fite BioPharma's return on equity of 0.00% beat Natural Alternatives International's return on equity.Company Net Margins Return on Equity Return on Assets Natural Alternatives International-6.26% -9.36% -4.82% Can-Fite BioPharma N/A N/A N/A SummaryCan-Fite BioPharma beats Natural Alternatives International on 11 of the 19 factors compared between the two stocks. Remove Ads Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CANF vs. The Competition Export to ExcelMetricCan-Fite BioPharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$5.45M$6.91B$5.64B$19.62BDividend YieldN/A2.73%4.57%3.75%P/E Ratio-0.867.2023.1333.60Price / Sales8.17226.01383.8927.47Price / CashN/A65.6738.1617.54Price / Book0.886.476.944.60Net Income-$7.63M$141.90M$3.20B$1.02B7 Day Performance-3.75%-3.20%-2.33%0.37%1 Month Performance-12.50%-5.64%2.84%-2.45%1 Year Performance-30.63%-7.47%10.75%5.03% Can-Fite BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CANFCan-Fite BioPharma2.2015 of 5 stars$1.54+1.3%$14.00+809.1%-31.9%$5.45M$667,000.00-0.868NAIINatural Alternatives International0.8016 of 5 stars$3.69-5.1%N/A-43.3%$22.87M$121.85M-2.86290Analyst ForecastShort Interest ↑News CoverageCDIOCardio Diagnostics2.8996 of 5 stars$0.43-4.0%$2.00+362.9%-69.8%$22.53M$35,688.000.001Short Interest ↓Gap UpFNCHFinch Therapeutics GroupN/A$14.00+2.2%N/A+403.5%$22.48M$110,000.00-1.59190ALLKAllakos4.6164 of 5 stars$0.25-1.4%$2.00+712.0%-81.7%$22.22MN/A-0.12190Short Interest ↓Positive NewsUBXUnity Biotechnology4.1495 of 5 stars$1.30-28.8%$6.00+361.5%-27.6%$21.93M$240,000.00-0.9960Analyst ForecastAnalyst RevisionHigh Trading VolumeENLVEnlivex Therapeutics2.9999 of 5 stars$1.02-2.4%$10.00+880.4%-73.8%$21.83MN/A-1.0470Upcoming EarningsAnalyst RevisionNews CoverageGap UpBIVIBioVie2.8889 of 5 stars$1.18+5.4%$3.00+154.2%+102.4%$21.77MN/A-0.1210Short Interest ↓News CoveragePMNProMIS Neurosciences0.7295 of 5 stars$0.65+1.5%N/A-60.0%$21.25MN/A-6.505Short Interest ↑Gap UpLIANLianBioN/A$0.20-2.3%N/A-38.0%$21.12MN/A-0.24110Gap DownNNVCNanoViricidesN/A$1.33+2.3%N/A+7.1%$20.80MN/A-1.8520 Remove Ads Related Companies and Tools Related Companies Natural Alternatives International Alternatives Cardio Diagnostics Alternatives Finch Therapeutics Group Alternatives Allakos Alternatives Unity Biotechnology Alternatives Enlivex Therapeutics Alternatives BioVie Alternatives ProMIS Neurosciences Alternatives LianBio Alternatives NanoViricides Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CANF) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CANF Stock Free CANF Stock Alerts